Virology Journal最新文献

{"title":"Characterization and genome analysis of lytic Vibrio phage VPK8 with potential in lysing Vibrio parahaemolyticus isolates from clinical and seafood sources.","authors":"Valalak Jintasakul, Jiranan Pattano, Sutima Preeprem, Pimonsri Mittraparp-Arthorn","doi":"10.1186/s12985-025-02637-6","DOIUrl":"10.1186/s12985-025-02637-6","url":null,"abstract":"<p><strong>Background: </strong>Vibrio parahaemolyticus is a marine bacterium causing seafood-associated gastrointestinal illness in humans and acute hepatopancreatic necrosis disease (AHPND) in shrimp. Bacteriophages have emerged as promising biocontrol agents against V. parahaemolyticus. This study characterizes Vibrio phage VPK8, focusing on host specificity, efficiency of plating (EOP) variability across V. parahaemolyticus isolates from diverse sources and other Vibrio species, morphology, genomic features, and bacteriolytic potential.</p><p><strong>Methods: </strong>Vibrio phage VPK8 was isolated from blood cockles in Thailand using a mixed-host approach and purified via the double-layer agar method. Host specificity was evaluated using spot assays and EOP measurements against 120 Vibrio strains, including AHPND-associated, clinical, and seafood isolates. Phage morphology was characterized by transmission electron microscopy (TEM), while genomic features were analyzed using next-generation sequencing. Lytic characteristics, including latent period and burst size, were determined through one-step growth curves, and bacterial growth reduction was evaluated over a 24-h.</p><p><strong>Results: </strong>Vibrio phage VPK8 is a lytic phage with a 42,866 bp linear double-stranded genome, G + C content of 49.4%, and 48 coding sequences. Phylogenetic analysis grouped it within the Autographiviridae family, showing 95.96% similarity to Vibrio phage vB_VpaP_MGD1. Viral proteomic analysis placed VPK8 within the Pseudomonadota host group. Spot assays indicated broad lytic activity, but EOP analysis revealed high infectivity in clinical and seafood V. parahaemolyticus isolates, as well as some V. cholerae and V. mimicus strains. TEM revealed an icosahedral head (~ 60 nm) and a short tail. At a multiplicity of infection of 0.01, VPK8 exhibited a latent period of 25 min, a burst size of 115, and effectively inhibited the reference host V. parahaemolyticus PSU5124 within 6 h, maintaining its lytic activity and stability for over 24 h.</p><p><strong>Conclusions: </strong>This study provides a detailed characterization of Vibrio phage VPK8 which exhibits targeted infectivity with high EOP in clinical and seafood V. parahaemolyticus isolates, as well as selected Vibrio species. Its stable lytic performance, rapid replication, and genomic safety suggest its potential for phage-based applications. Further studies should explore its in vivo efficacy and the genetic features contributing to phage resistance mechanisms, enhancing its potential applicability in managing Vibrio-related diseases.</p>","PeriodicalId":23616,"journal":{"name":"Virology Journal","volume":"22 1","pages":"21"},"PeriodicalIF":4.0,"publicationDate":"2025-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11783711/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143068349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"C-28 linker length modulates the activity of second-generation HIV-1 maturation inhibitors.","authors":"K C Yuvraj, Aradhana Singh, Sayantani Datta, Ritika Das, Pranjal Raj Saxena, Subash Chapagain, T J Nitz, Carl Wild, Ritu Gaur","doi":"10.1186/s12985-025-02635-8","DOIUrl":"10.1186/s12985-025-02635-8","url":null,"abstract":"<p><p>Maturation inhibitors (MIs) block HIV-1 maturation by preventing the cleavage of the capsid protein and spacer peptide 1 (CA-SP1). Bevirimat (BVM), a first-in-class MI, displayed sub-optimal efficacy in clinical trials due to presence of SP1:V7A polymorphism in the Gag protein.This polymorphism is inherently present in HIV-1 subtype C and conferred resistance to BVM. Second generation BVM analogs with modifications at C-28 position gained potent activity against HIV-1 subtype C. In this study, we have evaluated the efficacy of nine second-generation MIs (BVM analogs) with varying length of C28 carbon linker against HIV-1 subtype B and C. Increasing the length of carbon linker decreased their activity against both subtypes. These MIs were also active against integrase inhibitor-resistant viruses and protease inhibitor-resistant viruses. Our data has provided vital information that in addition to the nature of the functional group at C28 position of the MI, the length of linker contributes significantly to its activity. The shorter the length, the better the activity of MIs. These results will further pave way for design of novel and potent MIs.</p>","PeriodicalId":23616,"journal":{"name":"Virology Journal","volume":"22 1","pages":"20"},"PeriodicalIF":4.0,"publicationDate":"2025-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11776332/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143060820","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Deciphering the therapeutic effects of Xiyanping injection: insights into pulmonary and gut microbiome modulation, SerpinB2/PAI-2 targeting, and alleviation of influenza a virus-induced lung injury.","authors":"Tengwen Liu, Shuping Li, Xuerui Wang, Mingjiang Liu, Yuchen Wang, Jie Ying, Shuwen Zhang, Yan Lin, Ning Wang, Yungjing Bai, Lan Xie, Tengfei Chen, Quansheng Feng, Xiaolong Xu","doi":"10.1186/s12985-025-02636-7","DOIUrl":"10.1186/s12985-025-02636-7","url":null,"abstract":"<p><p>Infection with Influenza A virus (IAV) induces severe inflammatory responses and lung injury, contributing significantly to mortality and morbidity rates. Alterations in the microbial composition of the lungs and intestinal tract resulting from infection could influence disease progression and treatment outcomes. Xiyanping (XYP) injection has demonstrated efficacy in clinical treatment across various viral infections. However, its specific effects and mechanisms against IAV remain unclear. In this study, we established an IAV infection mice model, and utilized 16 S rRNA sequencing, RNA sequencing, protein chips, and molecular docking, to investigate the mechanisms of XYP injection on altering pulmonary and gut microbiota, and identifying its target sites. We revealed that XYP injection significantly reduced mortality, weight loss, lung viral titers, and lung pathology in IAV-infected mice. XYP injection down-regulated the activity of malondialdehyde, and the levels of interleukin (IL)-1β, IL-5, IL-6, tumor necrosis factor-α, IL-18, IL-15, granulocyte colony-stimulating factor, IL-9, chemokine (C-C motif) ligand-5, and C-X-C motif chemokine ligand 5, while up-regulated the activities of glutathione peroxidase reactive and superoxide dismutase, and the level of interferon-γ. The diversity of the pulmonary and gut microbiota was altered slightly after XYP injection. The linear discriminant analysis of the gut microbes revealed a higher proportion of potentially beneficial bacteria, including Akkermansia, Parabacteroides goldsteinii, Defluviitaleaceae, Oscillospirales, and Eubacterium_coprostanoligenes_group characterized the XYP group. Peritoneal macrophage RNA sequencing highlighted Serpinb2 as the most significantly regulated gene by XYP injection, along with consistent changes in multiple downstream Th2 structure genes. KEGG pathway analysis indicated significant modifications in genes associated with influenza A, mitogen-activated protein kinase signaling, nuclear factor kappa-B signaling, and apoptosis following XYP injection. Finally, human protein chips and molecular docking were carried out to confirm the binding of the main component of XYP injection, andrographolide, with SERPINB2/PAI-2 protein. Overall, our study provides valuable insights into the therapeutic potential of XYP injection in treating influenza, highlighting its multifaceted effects on host microbiota and immune responses, and pinpointing SerpinB2/PAI-2 as the target for XYP injection in exerting anti-inflammatory and antiviral therapeutic mechanisms.</p>","PeriodicalId":23616,"journal":{"name":"Virology Journal","volume":"22 1","pages":"19"},"PeriodicalIF":4.0,"publicationDate":"2025-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11776135/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143059112","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Detection of human noroviruses in sewage by next generation sequencing in Shandong Province, 2019-2021.","authors":"Suting Wang, Mingyi Xu, Xiaojuan Lin, Ping Xiong, Yao Liu, Aiqiang Xu, Meng Chen, Shengxiang Ji, Zexin Tao","doi":"10.1186/s12985-025-02638-5","DOIUrl":"10.1186/s12985-025-02638-5","url":null,"abstract":"<p><strong>Background: </strong>Human noroviruses are the major cause of acute gastroenteritis and exhibit considerable genetic diversity. Next generation sequencing (NGS) analysis based on environmental surveillance has been proved to be an effective method in norovirus surveillance.</p><p><strong>Methods: </strong>Between January 2019 and December 2021, 36 sewage samples were collected and analyzed using real-time quantitative PCR to detect noroviruses. Partial VP1 region was amplified and subjected to NGS analysis to assess the abundance and genetic characterization of various norovirus genotypes across different samples.</p><p><strong>Results: </strong>A total of 23 norovirus genotypes were identified, including 9 genotypes of GI, 13 genotypes of GII and 1 genotype of GIX. The most frequently detected genotypes were GI.5 (86.11%), GII.2 (86.11%), GII.4 (63.89%), GII.17 (58.33%), and GII.13 (55.56%). Additionally, some rare genotypes, such as GI.7, GII.5, GII.9, and GII.16, which had not been previously reported in Shandong, were identified. No significant differences were observed in genotypic diversity or viral copy numbers in sewage samples when comparing pre- and post-COVID-19 periods. A total of 379 partial VP1 sequences were obtained, with the means sequence identity within a genotype of Shandong sequences ranging from 92.69 to 98.37% and a coefficient of variation ranging from 1.46 to 6.73%. Phylogenetic analysis indicated that local noroviruses within each genotype comprised multiple co-circulating lineages.</p><p><strong>Conclusions: </strong>Our data demonstrate that sewage contains noroviruses with considerable high diversities. NGS based environmental surveillance greatly improves the understanding of norovirus circulation and should be encouraged.</p>","PeriodicalId":23616,"journal":{"name":"Virology Journal","volume":"22 1","pages":"18"},"PeriodicalIF":4.0,"publicationDate":"2025-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11773704/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143053659","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multiple gene-deletion vaccinia virus Tiantan strain against mpox.","authors":"Yilong Zhu, Dapeng Li, Renshuang Zhao, Minghua Chen, Yue Li, Xia Yang, Hongyue Mao, Xiao Li, Yiquan Li, Chao Shang, Xianzhu Xia","doi":"10.1186/s12985-025-02629-6","DOIUrl":"10.1186/s12985-025-02629-6","url":null,"abstract":"<p><p>Monkeypox virus (MPXV) is an important zoonotic pathogenic virus, which poses serious threats to public health. MPXV infection can be prevented by immunization against the variola virus. Because of the safety risks and side effects of vaccination with live vaccinia virus (VACV) strain Tian Tan (VTT), we constructed two gene-deleted VTT recombinants (TTVAC7 and TTVC5). The immunogenicity and protective effects of the gene-deleted VTT vaccine were assessed using BALB/C mice challenged with VTT and New Zealand rabbits challenged with MPXV. The results demonstrated strong humoral and cellular immune responses. The VTT-specific and neutralizing antibody titers, specific T cell levels, and degree of dendritic cell maturation of the mice, in addition to the MPXV neutralizing antibody titers and IFN-γ, IL-6, and TNF-α levels of the rabbits were markedly higher in the groups immunized with TTVAC7 and TTVC5 than the control groups (p < 0.05). Moreover, immunization with TTVAC7 and TTVC5 reduced morbidities caused by VACV and MPXV infection. The weight change, lung histological score, and residual virus of the mouse model (p < 0.05). Similarly, the temperature change, pock number, lung histological score, and residual virus of the rabbit model were significantly reduced in the groups immunized with TTVAC7 and TTVC5 (p < 0.05). Collectively, these results demonstrate that TTVAC7 and TTVC5 may be used as potential live attenuated vaccines against MPXV infection.</p>","PeriodicalId":23616,"journal":{"name":"Virology Journal","volume":"22 1","pages":"17"},"PeriodicalIF":4.0,"publicationDate":"2025-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11762464/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143042312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of SHEN26, a novel oral small molecular RdRp inhibitor for COVID-19 treatment: a multicenter, randomized, double-blinded, placebo-controlled, phase II clinical trial.","authors":"Jiangtao Bai, Tetsuya Asakawa, Wenfang Yuan, Yuanlong Lin, Hao Ju, Dandan Xu, Mingming Yang, Shuo Li, Guanguan Li, Deyin Guo, Hongzhou Lu, Xumu Zhang","doi":"10.1186/s12985-025-02631-y","DOIUrl":"10.1186/s12985-025-02631-y","url":null,"abstract":"<p><strong>Background: </strong>SHEN26 (ATV014) is an oral RNA-dependent RNA polymerase (RdRp) inhibitor with potential anti-SARS-CoV-2 activity. Safety, tolerability, and pharmacokinetic characteristics were verified in a Phase I study. This phase II study aimed to verify the efficacy and safety of SHEN26 in COVID-19 patients.</p><p><strong>Methods: </strong>This was a multicenter randomized double-blind placebo-controlled study. Mild-to-moderate adult patients with COVID-19 were recruited and randomly assigned to the high-dose (400 mg), low-dose (200 mg), or placebo groups (1:1:1). The primary outcome measure was \"changes in RNA levels on Day seven (D7)\". The second outcome measures were \"changes of RNA levels on D3, D5, D10, D28,\" \"Time of clearance of virus.\"</p><p><strong>Results: </strong>A total of 91 patients were recruited in this study between December 08, 2022, and January 27, 2023. Twelve patients dropped out due to a lack of examination results. Finally, the data of 79 patients (24 in the placebo group, 31 in the 200 mg group, and 24 in the 400 mg group) were analyzed. No significant differences in the baseline data were observed between the groups. The changes of viral load were significantly higher on D3 (P = 0.0119), and D5 (P = 0.0120) in 400 mg group (vs. placebo group), and the difference value achieved 1.06 log10 copies/mL on D3 and 1.21 log10 copies/mL on D5. No significant difference was found in the viral clearance time between SHEN26 administrating groups and placebo groups. Administration of SHEN26 did not enhance drug-related ADEs and did not induce ADEs, and ADE inducing drug withdrawal, dose reduction, or death. Moreover, SHEN26 did not worsen the renal function.</p><p><strong>Conclusions: </strong>Our findings indicate a better efficacy of a high dose (400 mg) for COVID-19 treatment. These preliminary data on the efficacy and safety provide useful information and a working basis for further verification and development of SHEN26 as a novel oral small-molecule antiviral drug for treating COVID-19.</p>","PeriodicalId":23616,"journal":{"name":"Virology Journal","volume":"22 1","pages":"16"},"PeriodicalIF":4.0,"publicationDate":"2025-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11762885/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143042298","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of host immune responses to Mycobacteriophage Fionnbharth by route of delivery.","authors":"Thomas Smytheman, Tiffany Pecor, Dana E Miller, Debora Ferede, Suhavi Kaur, Matthew H Harband, Hazem F M Abdelaal, Carlos A Guerrero-Bustamante, Krista G Freeman, Whitney E Harrington, Lisa M Frenkel, Graham F Hatfull, Rhea N Coler, Sasha E Larsen","doi":"10.1186/s12985-024-02552-2","DOIUrl":"10.1186/s12985-024-02552-2","url":null,"abstract":"<p><p>For much of the last decade, tuberculosis (TB) was the leading cause of mortality due to an infectious pathogen (Mycobacterium tuberculosis, M.tb). Approximately 1.3 million deaths in 2023 worldwide were attributed to TB disease. Focused intervention strategies to block transmission would significantly reduce the global health burden of TB. Mycobacteriophages (phages) are a sorely underutilized biologic therapy for the pathogen M.tb, and here we aimed to address outstanding questions about their utility for clinical applications. We aimed to determine the impact of repeated mucosal or intravenous (IV) delivery of representative anti-M.tb phage FionnbharthΔ45Δ47 (Fionnbharth) in a preclinical mouse model. In addition, we specifically sought to understand which route induced anti-phage antibodies, which may reduce the long-term impact of phage therapy. C57BL/6 mice were dosed weekly for 6 weeks by either route and serum and bronchoalveolar lavage fluid (BALf) were evaluated for anti-phage humoral responses by ELISA. We found that aerosol delivery disperses phage across all lung lobes where M.tb is also found after experimental infection by the same route. Repeated aerosol delivery was well tolerated and did not induce robust neutralizing humoral immunity. In contrast, Mice receiving IV phage developed increasing magnitude and neutralizing total IgG and IgA responses over time. To determine whether pre-treatment environmental exposure to Fionnbharth-like phages could induce antibody responses that are potentially neutralizing, ~ 500 human plasma samples from normal donors were evaluated by ELISA. We observed that 5% of samples had antibodies to Fionnbharth (with end point titers > 10^- 3 dilution), although none were neutralizing. Furthermore, we found that highly-purified phage preparations did not activate mouse or human derived toll like receptor (TLR) 4 or TLR9 in HEKblue reporter assays. These data together support using Fionnbharth in anti-M.tb therapy phage cocktail strategies and that aerosol delivery should be prioritized for further efficacy testing.</p>","PeriodicalId":23616,"journal":{"name":"Virology Journal","volume":"22 1","pages":"14"},"PeriodicalIF":4.0,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11748884/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143012529","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incidence and estimated risk of residual transmission of hepatitis a virus and parvovirus B19 by blood transfusion in the state of Rio De Janeiro - Brazil: a retrospective study.","authors":"Arthur Daniel Rocha Alves, Mariana Magaldi, Ana Carolina Sathler de Menezes, Josiane Iole França Lopes, Carlos Alexandre da Costa Silva, Jaqueline Mendes de Oliveira, Camila Mattos, Leonardo Bastos, Luiz de Melo Amorim Filho, Marcelo Alves Pinto, Luciane Almeida Amado","doi":"10.1186/s12985-025-02627-8","DOIUrl":"10.1186/s12985-025-02627-8","url":null,"abstract":"<p><strong>Background: </strong>Nonenveloped viruses, such as hepatitis A virus (HAV) and parvovirus B19 (B19V), are not inactivated by detergents and solvents commonly used to manufacture plasma derivatives. Cases of transfusion-transmitted HAV and B19V have already been described in several countries. This study aimed to determine the incidence of HAV and B19V asymptomatic infections in blood donors from Rio de Janeiro and evaluate the residual risk of transmission to blood derivative recipients.</p><p><strong>Methods: </strong>From 2018 to 2019, 1,204 plasma samples were tested by PCR and real-time PCR. HAV and B19V genotypes were determined through sequencing and phylogenetic analysis. The risk of transfusion transmission was determined using a Bayesian statistical approach.</p><p><strong>Results: </strong>HAV-RNA and B19V-DNA were detected in 1.66 (95% CI 0.26-5.48) and 3.32 (95% CI 1.00-7.81) per 1000 donors, respectively. For HAV, all positive samples were classified as subgenotype IB. For B19V, the sequenced samples belonged to genotype 1A. The estimated numbers of infectious blood bags with HAV and B19V were 587 (95% CI 92-1936) and 880 (95% CI 355-2759), respectively.</p><p><strong>Conclusion: </strong>This study originally assessed the incidence of both Hepatitis A Virus (HAV) and B19 Virus (B19V) among Brazilian blood donors, as well as the potential risk of residual transmission of these infections through blood transfusions. Our findings can contribute to future cost-effective studies aimed at implementing screening methods for these viruses, which could enhance discussion on surveillance in blood banks and protective measures for blood recipients.</p>","PeriodicalId":23616,"journal":{"name":"Virology Journal","volume":"22 1","pages":"15"},"PeriodicalIF":4.0,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11749351/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143012512","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of human leukocyte antigen in HTLV-1 infection and progression to ATLL and HAM/TSP: a systematic review and meta-analysis.","authors":"Shayan Mardi, Maryam Rashidian, Fatemeh Bastan, Ghazale Molaverdi, Sayed-Hamidreza Mozhgani","doi":"10.1186/s12985-024-02612-7","DOIUrl":"10.1186/s12985-024-02612-7","url":null,"abstract":"<p><strong>Background: </strong>Human T-cell lymphotropic virus type 1 (HTLV-1) is a retrovirus that leads to lifelong infection and multiple diseases, including HAM/TSP and ATLL. Despite extensive research, the exact pathophysiology of HTLV infection and its related diseases is enigmatic. In this study, we aimed to review and analyze the effect of different HLA alleles as protective or predisposing factors in HTLV-1 infection and its progression to related diseases.</p><p><strong>Method: </strong>Three databases (PubMed, Web of Science, and Scopus) were searched for eligible studies. Twenty-five papers with 7279 participants were included in the quantitative analysis. The relevant data were extracted, and 198 meta-analyses were conducted on each reported HLA and population.</p><p><strong>Results: </strong>The results of our investigation suggest 3 HLAs with preventive effects against HTLV infection, including HLA-B*35, DRB1*09, and DRB1*16. Also, HLA-DQB1*05:01 might prevent HTLV progression to ATLL. In contrast, HLA-DRB1*13 is more prevalent in ATLL patients than HTLV carriers. Additionally, our results propound that carriers of HLA-A*28, B*54, C*07, DQB1*03:01, and DRB1*07:01 are at higher risk, and carriers of HLA-A*30, B*37, B*40, B*44, C*08, DQB1*06:02, and DRB1*15:01 are in lower risk of HTLV progression to HAM/TSP. We concluded that the mentioned HLA alleles are potential biomarkers of HTLV infection and its progression to related diseases.</p>","PeriodicalId":23616,"journal":{"name":"Virology Journal","volume":"22 1","pages":"13"},"PeriodicalIF":4.0,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11749399/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143012537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Construction of a Vero cell line expression human KREMEN1 for the development of CVA6 vaccines.","authors":"Dongqing Zhang, Yuxiang Zou, Jiaying Wu, Longfa Xu, Zhifeng Ke, Yuanyuan Wu, Zhenhong Zhou, Mujin Fang, Ling Chen, Henggang Xu, Jianping Chu, Ningshao Xia, Rui Zhu, Tong Cheng","doi":"10.1186/s12985-024-02618-1","DOIUrl":"10.1186/s12985-024-02618-1","url":null,"abstract":"<p><p>Coxsackievirus A6 (CVA6) has emerged as a major pathogen causing hand, foot and mouth disease (HFMD) outbreaks worldwide. The CVA6 epidemic poses a new challenge in HFMD control since there is currently no vaccine available against CVA6 infections. The Vero cell line has been widely used in vaccine production, particularly in the preparation of viral vaccines, including poliovirus vaccines and EV71 vaccines. Unfortunately, most CVA6 strains failed to propagate effectively on Vero cells. The expression level of virus-specific receptors on the cell membrane significantly influences viral infection. Here, a Vero cell line with stable over-expressing of KREMEN1 (KRM1), a crucial receptor for CVA6, was constructed using the lentivirus system. The cloned cell line, called Vero-KRM1_#11, could efficiently support most CVA6 infections. The propagation of CVA6-TW00141 strain on Vero-KRM1_#11 was equal to that on RD cells. After four passages, the virus batch was obtained with a titer of about 10⁷ TCID₅₀/mL. Moreover, the purified CVA6 particles produced from Vero-KRM1_#11 or RD cells both could induce high and comparable levels of IgG and neutralizing antibodies. Importantly, passive transfer of the antisera from CVA6-vaccined mice showed 100% preventive efficacy against CVA6 infection in mice. Therefore, KRM1-expressing cells have the potential to serve as a valuable tool for the development and production of CVA6 or polyvalent HFMD vaccines.</p>","PeriodicalId":23616,"journal":{"name":"Virology Journal","volume":"22 1","pages":"12"},"PeriodicalIF":4.0,"publicationDate":"2025-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11742515/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143012503","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}